[ad_1]
Horizon Discovery Group plc, a global leader in applying gene editing and gene modulation to cell line engineering, today announced that it has granted two commercial licenses for its cGMP-compliant CHOSOURCE ™ platform to Sanyou Biopharmaceuticals Co., Ltd., a leading biotechnology company focused on the research, development and supply of integrated solutions for the development of innovative antibody drugs.
Sanyou will use Horizon’s modified K1 knockout glutamine synthetase (GS) cell line to develop preclinical antibody drug projects and to support the clinical development and commercialization of its customers’ human biotherapy products. as a platform offering through its contract research services.
Sanyou is a leader Biotechnology company with extensive experience in early stage drug discovery, IND archiving, and clinical trial management. The company has established an integrated research and development laboratory for innovative antibody drugs and we are delighted that CHOSOURCE has been selected to support its biotherapeutic pipeline and contract research service offering. “
Jesús Zurdo, Global Head Bioproduction Business Unit, Horizon Discovery.
“Horizon is committed to supporting innovative organizations of all sizes to enhance biotherapeutic manufacturing using our expression platform. We are proud to have licensed CHOSOURCE to over 80 organizations, from nonprofit and early stage startups to clinical stage biotechnology and large pharmaceutical companies, and we have helped to enable at least 8 biotherapeutics expressed in these cells to progress in studies clinical. “
Horizon’s CHOSOURCE facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins and is recognized in industry and regulators for high throughput manufacturing. This robust platform will be critical to enabling us to generate stable cell lines for the development of antibody drugs, diagnostic products and cell therapy related components and will enable us to provide a stronger one-stop solution to our customers with IND-ready designs through our contract research services and collaborations that enrich the pipeline. ”
Dr. David Lang, CEO, Sanyou Biopharmaceuticals Co., Ltd
Horizon’s protocols and proprietary GS knockout CHO cell line have a proven track record in the discovery and development of biopharmaceuticals, from transient expression for research applications to the development of stable cell lines for clinical and commercial production of biotherapy drugs, including new ones. multi-specific products and complex molecular architectures.
The company licenses its CHOSOURCE expression system to pharmaceutical, biotech and biosimilar companies, as well as contract manufacturing organizations.
For more information on Horizon’s CHO expression system, please visit: https://horizondiscovery.com/en/chosource
.
[ad_2]
Source link
